Geron’s stock soars 95% after FDA advisory panel votes in favor of blood-disorder drug

Geron Corp.’s stock rose 95% Friday, after an advisory panel to the Food and Drug Administration voted 12-to-2 in favor of the company’s blood-disorder drug imetelstat and said its benefits outweigh the risks.

Previous post Realtor group agrees to cut commissions to settle lawsuits, in a move that could reshape home sales
Next post A Silent Recession: Why You Might Feel Bad Despite A Good Economy